A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
10/2004
10/13/2004	EP1408910A4 Stable cosmetic emulsion with polyamide gelling agent
10/13/2004	EP1257584B1 Humanized antibodies that sequester amyloid beta peptide
10/13/2004	EP1165069B1 Antitumour synergistic composition
10/13/2004	EP1107746B1 Methods of using and compositions comprising dopamine reuptake inhibitors
10/13/2004	CN1537112A Pyrimidine compound
10/13/2004	CN1537101A Pyridine matrix metalloproteinase inhibitors
10/13/2004	CN1537008A Pharmaceutical combination comprising either (S)-20ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy)phenyl] propanoic acid
10/13/2004	CN1537007A 2 methyl-thieno-benzodiazepine lyophilizde formulation
10/13/2004	CN1536993A Solid pharmaceutical composition comprising 4-cyano-trifluoro-N-[3-(40fluorophenylsulphonyl)2-hydroxy-2-methylpropiono]-m-toluidide and PVP
10/13/2004	CN1170817C 前列腺素e类似物 E prostaglandin analogs
10/12/2004	US6803361 Administering nucleotide sequence
10/07/2004	WO2004084843A2 Inhibitors of cathepsin s
10/07/2004	WO2004084842A2 Inhibitors of cathepsin s
10/07/2004	WO2004084839A2 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
10/07/2004	WO2004084838A2 Identification, quantification, and characterization of t cells and t cell antigens
10/07/2004	WO2004084837A2 Methods and compositions for treating and preventing inflammatory conditions
10/07/2004	WO2004084836A2 Methods for treating taxol-induced gut disorder
10/07/2004	WO2004084835A2 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
10/07/2004	WO2004084833A2 Jucara and açai fruit-based dietary supplements
10/07/2004	WO2004084832A2 Measurement of estrogen activity in plants and a composition therefrom
10/07/2004	WO2004084831A2 Optimized expression of hpv 31 l1 in yeast
10/07/2004	WO2004084830A2 Method for treating alzheimer’s dementia
10/07/2004	WO2004084829A2 Esterified fatty acid composition
10/07/2004	WO2004084828A2 Keratinocyte-fibrocyte concomitant grafting for wound healing
10/07/2004	WO2004084827A2 Reduction of zinc-induced neurotoxic injury by blockade of nitric oxide synthesis
10/07/2004	WO2004084825A2 Wound healing composition derived from low platelet concentration plasma
10/07/2004	WO2004084824A2 Biaryl substituted 6-membered heterocyles as sodium channel blockers
10/07/2004	WO2004084822A2 Methods for inducing immune tolerance
10/07/2004	WO2004084821A2 Hemipteran glutamate decarboxylase
10/07/2004	WO2004084820A2 Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
10/07/2004	WO2004084819A2 Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
10/07/2004	WO2004084818A2 Measurement of estrogen activity in plants and a composition therefrom
10/07/2004	WO2004084816A2 IMPROVED CD4-IgG2 FORMULATIONS
10/07/2004	WO2004084815A2 Virulence genes of h. pylori in gastric cancer
10/07/2004	WO2004084814A2 High viscosity xanthan polymer preparations
10/07/2004	WO2004084813A2 Chemical compounds
10/07/2004	WO2004084812A2 Tamandarin analogs and fragments thereof and methods of making and using
10/07/2004	WO2004084811A2 Crystals and structures of epidermal growth factor receptor kinase domain
10/07/2004	WO2004084810A2 Novel imidazoline receptor homologs
10/07/2004	WO2004084809A2 Neuroprotective macrocylic compounds and methods for their use
10/07/2004	WO2004084808A2 Animal with surgically modified gastrointestinal tract and method for study of weight reduction
10/07/2004	WO2004084807A2 Micro-cluster compositions
10/07/2004	WO2004084806A2 Protein modification and maintenance molecules
10/07/2004	WO2004084805A2 Acetylated tat polypeptides and methods of use thereof
10/07/2004	WO2004084804A2 Detection and monitoring of lung cancer
10/07/2004	WO2004084801A2 Treatments for leishmaniasis
10/07/2004	WO2004084800A2 A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
10/07/2004	WO2004084799A2 Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
10/07/2004	WO2004084797A2 Type 2 diabetes mellitus-associated gene and utilization of the same
10/07/2004	WO2004084705A2 Quantitative detection of h. pylori in biological samples
10/07/2004	WO2004069171A3 Novel compounds for the treatment of sickle cell disease
10/07/2004	WO2004067698A3 Helminth-derived antigens having capacity of providing protection against parasites
10/07/2004	WO2004066924A3 Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
10/07/2004	WO2004066913A3 Solid mosapride preparation
10/07/2004	WO2004066910A8 Controlled release modifying complex and pharmaceutical compositions thereof
10/07/2004	WO2004054514A3 C-6 modified indazolylpyrrolotriazines
10/07/2004	WO2004052314A3 Antimicrobial suture coating
10/07/2004	WO2004045517A3 Method for the diagnosis and treatment of vascular disease
10/07/2004	WO2004041168A3 Compositions and methods for prevention of photoaging
10/07/2004	WO2004041164A3 Kinase inhibitors
10/07/2004	WO2004039327A3 Use of equol for treating androgen mediated diseases
10/07/2004	WO2004037165A3 Nitric oxide and its biomedical significance
10/07/2004	WO2004034980A3 Treatment for traumatic synovitis and damaged articular cartilage
10/07/2004	WO2004028466A3 Ketoamide inhibitors in chronic nerve disease
10/07/2004	WO2004021999A3 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
10/07/2004	WO2004010934A3 Methods for the use of neurotoxin in the treatment of urologic disorders
10/07/2004	WO2004009014A3 Systems and methods for monitoring and enabling use of a medical instrument
10/07/2004	US20040198828 Combinational use of long-acting and short-acting anti-histamines for ocular allergies
10/07/2004	US20040198816 Administering mixture of anesthetic and adrenergic receptor antagonist; reverse with low dosage of adrenergic receptor antagonist; used for hair grafting
10/07/2004	US20040198808 Halogenated triptolide derivatives as immunomodulators and anticancer agents
10/07/2004	US20040198787 Efficient process for the preparation of a factor Xa inhibitor
10/07/2004	US20040198782 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration
10/07/2004	US20040198780 osteoporosis; antiarthritic agents; antidiabetic aghents; Alzheimer's disease; shock; central nervous system disorders; anticancer agents
10/07/2004	US20040198754 using theobromine; controlling weight; side effect reduction
10/07/2004	US20040198739 Prevention reproduction of virus
10/07/2004	US20040198706 active agent (not testosterone alone ) and a delivery vehicle containing an alkanol, a polyalcohol, and a permeation enhancer to provide permeation enhancement of the active mammalian dermal or mucosal surface; free of long chain fatty acid, fatty ester and fatty alcohol to avoid odor and irritation
10/07/2004	US20040198685 For prophylaxis and therapy of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen
10/07/2004	US20040197413 Microparticle formation system; forming a plurality of droplets of the solution using a spray head in fluid communication with the solution source; low polydispersity, controlled integrity (e.g. shape and morphology) and stability (e.g., against aggregation)
10/07/2004	US20040197319 Wound healing composition derived from low platelet concentration plasma
10/07/2004	US20040197303 For therapy of inflammation and diseases or conditions associated with autoimmune responses
10/07/2004	US20040197282 Method and preparation containing idebenone for protecting human skin
10/07/2004	US20040194233 Containing 2-electron oxidoreductases, electron donors, basic amino acids and oxidation bases; ready to use; homogeneous, intense, chromatic colorations; does not degrade hair; long lasting, wash resistance
10/07/2004	CA2529584A1 Jucara and acai fruit-based dietary supplements
10/07/2004	CA2520675A1 Identification, quantification, and characterization of t cells and t cell antigens
10/07/2004	CA2520512A1 Methods, compositions and kits for the detection and monitoring of lung cancer
10/07/2004	CA2519677A1 Biaryl substituted 6-membered heterocycles as sodium channel blockers
10/07/2004	CA2519488A1 Micro-cluster compositions
10/07/2004	CA2519234A1 Tamandarin analogs and fragments thereof and methods of making and using
10/07/2004	CA2519114A1 Methods and compositions for treating and preventing inflammatory conditions
10/07/2004	CA2518854A1 Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
10/07/2004	CA2516163A1 High viscosity xanthan polymer preparations
10/06/2004	EP1464640A2 20-Epi-16-ene-25-OH-D3-analogs
10/06/2004	EP1463797A2 Methods of kidney transplantation utilizing developing nephric tissue
10/06/2004	EP1463576A2 Mesoporous permeation layers for use on active electronic matrix devices
10/06/2004	EP1463519A2 Vaccine
10/06/2004	EP1463412A2 Composition comprising wenguanguo extracts, methods for preparing same and uses therof
10/06/2004	EP1202743B1 Pharmaceutical and cosmetic compositions comprising cod serine proteases and their pharmaceutical and cosmetic use
10/06/2004	EP1165716B1 Adhesives
10/06/2004	EP0964667B1 Bar composition comprising low viscosity oils pre-thickened by non-antifoaming hydrophobic polymers
10/06/2004	EP0869810B1 Cyclosporin-containing soft capsule preparations

1 ... 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 ... 295